+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.

Age: 18Years +All GendersPhase 4
149 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
M

Actively Recruiting

Researchers are evaluating the use of an ECG-based artificial intelligence device to help predict if people with interstitial lung disease ILD are at high risk for undiagnosed pulmonary hypertension PH. The study aims to see whether using this device increases the number of new PH diagnoses over six months compared to standard care. This multi-center randomized trial focuses on adults diagnosed with ILD and assesses how well the AI device performs in clinical practice. Participants with ILD will each receive a 12-lead electrocardiogram ECG that the AI device analyzes to identify those at high risk for PH. Participants will be randomly assigned to either receive the device results or not. Those in the device group identified as high risk will undergo additional tests including an echocardiogram and right heart catheterization RHC. Other participants will continue with their usual care, which may include those tests if their doctor recommends them. During the study, participants will be followed for approximately six months to monitor new diagnoses of pulmonary hypertension. The research team will review how many participants receive new PH diagnoses in the different groups. Standard clinical care will continue throughout, and participants will have relevant heart and lung assessments as needed. The study will help determine if the AI device improves detection of pulmonary hypertension in people with ILD.

Age: 18Years +All GendersPhase Not Applicable
41 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations
S

Actively Recruiting

This research aims to evaluate how well NeoThelium FT Amnion Skin Graft works and how safe it is for treating chronic pressure ulcers. The study will take place at multiple medical centers using an open-label design, meaning both patients and researchers will know which treatment is being given. It is a post-marketing study intended to gather information on the treatments effectiveness and to support insurance reimbursement decisions. Participants will receive standard care plus weekly applications of NeoThelium FT, which is a dehydrated wound covering made from donated human placental tissue with amnion and chorion layers. Treatment includes wound cleansing, sharp debridement, applying NeoThelium FT, dressing for moisture balance, and offloading to reduce pressure. Patients will continue follow-ups according to the original schedule. During the study, participants will be assessed for wound healing progress including complete wound closure within 1 to 16 weeks, percent area reduction, wound closure at 2 weeks, and the number of grafts used. Researchers will monitor safety and treatment adherence throughout the study period, which is expected to last up to 16 weeks. This helps understand the treatments impact on chronic pressure ulcers over time.

Age: 18Years +All GendersPhase Not Applicable
2 locations

1-10 of 12

1